Alnylam Pharmaceuticals, Inc. (ALNY) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 Yvonne L. Greenstreet.
ALNY 을(를) 보유 IPO 날짜 2004-06-01, 2,230 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $45.01B.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel RNAi (RNA interference) therapeutics for genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company has three marketed products: ONPATTRO for hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Alnylam maintains a robust pipeline of investigational therapies addressing hemophilia, hypertension, hypercholesterolemia, and metabolic liver disease, supported by strategic collaborations with Regeneron Pharmaceuticals and Sanofi Genzyme. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company has established multiple license and collaboration agreements with leading pharmaceutical organizations to advance RNAi-based drug development.
